[...] we lacked data about laboratory results including international normalized ratio for patients who were on VKAs and time in therapeutic range.[...] our study included only patients from the Medicare population and might not be generalizable to other patients.[...] patients with cardiac amyloidosis admitted with heart failure and new-onset AF had better outcome when prescribed DOACs compared with VKAs with decreased risk of mortality, ischemic stroke, and major bleeding events. Disclosures Dr. Desai is a consultant for Medtronic and Bristol-Myers Squibb.